Among a wave of fresh approvals and launches in the US, Aurobindo has recently announced the launch of its generic rival to Gilead Sciences’ Truvada (emtricitabine/tenofovir disoproxil) 200mg/300mg tablets, after receiving full abbreviated new drug application approvals from the US Food and Drug Administration. The company also launched a generic of Gilead’s triple-combination Atripla (efavirenz/emtricitabine/tenofovir disoproxil) tablets in 600mg/200mg/300mg doses.
Aurobindo’s Latest Launches Include Truvada And Atripla Rivals
As Company Plans To Broaden Its Injectables Generics Portfolio In China
Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market.
